HIV: Science, Sex and Society. Lecture 2. Strategies for the cure of HIV-1. Mario Stevenson, Ph.D Department of Medicine.

Slides:



Advertisements
Similar presentations
New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
Advertisements

Measuring the latent HIV Reservoir
HIV treatment as prevention Stephen Kegg. 2 Learning Outcomes Overview of HIV management HIV transmission risks Current prevention strategies Which new.
Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.
Section 22.4 Protecting Yourself From HIV and AIDS Objectives
ANIMAL MODELS HIV Cure Research Training Curriculum The HIV CURE training curriculum is a collaborative project aimed at making HIV cure research science.
Pediatric HIV “Cure” HIV Cure Research Training Curriculum
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.
Chronic diseases in HIV Francois Venter Wits Reproductive Health & HIV Institute
Over 50 million HIV/AIDS cases have occurred worldwide Over 40 million people are currently living with HIV/AIDS 95% of all cases are in developing countries.
EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.
Current HIV basic science research topics. Toddler "Functionally Cured" of HIV Infection- “the Mississippi Baby” First well-documented case of an HIV.
Measuring the latent HIV Reservoir
Adj. Assistant Professor, UCLA Department of Medicine
Hematopoietic stem cell based gene therapy for HIV diseases
David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.
Blocviroc – an innovative treatment for HIV/AIDS Steve English Development Head, Antivirals.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
Undetectable = Uninfectious ? Treatment as Prevention.
2 About HIV: Teaching Tool. About HIV: A teaching tool © 2nd edition 2006 This tool was developed by the François-Xavier Bagnoud Center at the University.
HIV Basics. What is HIV? Human Immunodeficiency Virus ◦ Two Strains  HIV-1  HIV-2 Kills special blood cells that help fight off infections ◦ CD4+ Virus.
Future directions in HIV basic science research The hunt for a cure.
By David Velasquez Mr. Ippolito Biology Per. 8-9.
Chapter 21 Preview Bellringer Key Ideas What Are HIV and AIDS?
Halt and Reverse: HIV/AIDS. History Discovered in 1980s Originally linked to gay males first blood test approved In 1986, AZT, a failed cancer.
Chapter 12 ppt 3 The Lymphatic System Disorders
IAS 2012 feedback: UK Consortium: September 2012 IAS 2012 Feedback: New findings, better drugs and the goal of a cure Simon Collins HIV.
AIDS supplement. History of HIV Originated in Africa in the late 1950’s Originally found in nonhuman primates and may have mutated First documented in.
Novel Approaches: Treatment and HIV Pathogenesis L. Trautmann, Ph.D. VGTI Florida.
Global HIV Resistance: The Implications of Transmission
VIRUSES Tobacco mosaic virus Influenza virus Adenovirus Bacteriophage.
HIV/ AIDS.
“ Be Human. Value Life.” HIV/AIDS. What is HIV? Human Immunodeficiency Virus Retrovirus- known for long incubation periods, prolonged illness The HIV.
HIV Cure Research Updates Dr. Matthew Marsden UCLA Department of Medicine.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
Future directions in HIV basic science research The hunt for a cure.
The Berlin Patient and CCR5. Tim Brown: the only man to have been cured of HIV  Brown was diagnosed with HIV in 1995  11 years on antiretroviral therapy.
I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.
Functional cure after long term HAART initiated during early HIV infection - a case study. van Lunzen J. 1,2, Schulze zur Wiesch J. 1,2, Schumacher U.
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
Future directions in HIV basic science research The hunt for a cure.
What is gene therapy? Do now: In your own words,
Transmission of HIV from mother to fetus. - is not simply one of the major health problems today, but also a big problem in the field of human rights.
Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.
IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.
CURRENT HEALTH PROBLEMS IN STUDENT'S HOME SOUNTRIES HEPATITIS B IN MALAYSIA MOHD ZHARIF ABD HAMID AMINUDDIN BAKI AMRAN.
HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.
The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,
Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland Update on HIV Cure Research FORMATTED:
Grinsztejn B, et al, Lancet Infect Dis, March 4 th 2014 PRIMARY COMBINED M&M OUTCOME FIRST AIDS DEFINING EVENT FIRST TB EVENT DEATH.
Immune reconstitution Anjie Zhen, PhD
2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of.
A Call to Action Children – The missing face of AIDS.
HIV/GUM research update Dr Amanda Clarke Consultant in HIV/GUM & Clinical Trials, BSUH. 16 Nov 2015 LES GPs.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Davey Smith, MD Professor of Medicine University of California San Diego La Jolla, California When Will It All Be Over? HIV Cure Efforts Los Angeles, California:
Create a concept map of the adaptive immune system.
Prolonged HIV-1 Remission and Viral Rebound in an Individual Treated During Hyperacute Infection Timothy Henrich, Hiroyu Hatano, Alison Hill, Oliver Bacon,
State of HIV Cure Research
What’s Your Health IQ? True or False
Feedback meeting September 2017
AIDS supplement.
Hiv.
The block-and-lock approach
HIV.
Module 1: Overview of HIV Infection
Lesson 3: Treatment as Prevention
Undetectable = Untransmittable
Presentation transcript:

HIV: Science, Sex and Society. Lecture 2. Strategies for the cure of HIV-1. Mario Stevenson, Ph.D Department of Medicine.

Main topics: Review of the obstacles to viral eradication Treatment as prevention Berlin Patient; Visconti Patients; Mississippi Baby; Boston Patients Gene therapy approaches Shock and kill Immune-based strategies

Question: What was likely the most important component of Timothy Brown’s treatment that led to him being cured of HIV infection? A: He also had leukemia B: He received an experimental vaccine C: His treatment was started early after he first became infected D: He received a bone marrow transplant from an individual with a CCR5 mutation E: All of the above

Mechanisms of HIV persistence T cell survival Homeostatic proliferation Ongoing viral replication Finzi et al. Science 1997 ; Wong et al. Science 1997 ; Chun et al. PNAS 1997 ; Palmer et al. PNAS 2008 ; Chomont et al. Nat Med 2009 Active reservoir Latent reservoir Courtesy N. Chomont

Treatment as prevention: The power of PreP! Treatment as prevention: The power of PreP!

Time on antiviral cocktails (ART) virus particles in plasma (log10) Antiviral treatment: impact on transmission Years

months on antiviral cocktails (ART) virus particles in plasma (log10) Antiviral treatment: impact on transmission When an infected individual has low viral load on therapy, that individual does not transmit the virus!

PARTNER Cohort – Follow-up of Serodiscordant Couples when HIV+ Partner Has Suppressed Viral Load Behavior - HIV Neg Partner # Condomless Sex Acts Observed Linked Transmissions 95% CI (transmissions/100 CYFU) HT - Receptive Vaginal Intercourse13, HT - Insertive Vaginal Intercourse14, MSM - Receptive Anal Intercourse7, MSM - Insertive Anal Intercourse11, Rodger A, et al. 21st CROI Meeting, Boston, MA; March 3-6, Abst. 153LB.

Prior to exposure Time of transmission After infection PrEPPEPART Using Antiretroviral Medications for HIV-1 Prevention PreP trial HPTN 052: 1763 discordant couples (1 partner infected, the other uninfected) in nine countries. Infection and clinical status was monitored. Both partners started on ARVs immediately or after delayed interval.

HPTN 052: HIV-1 Transmissions 96% Decrease Cohen MS, Chen YQ, McCauley M, et al. N Engl J Med 2011; 365(6):493.

The Global iPrEx Study Use antivirals in high-risk individuals to prevent infection- a drug-based vaccine Limitations Success depends on how well enrollees took the drugs and stayed on the drugs. New formulations of drugs last for months after single dose.

34 MILLION PEOPLE LIVE WITH HIV/AIDS WORLDWIDE A cure is needed!

Current therapies are extremely effective - reduced pill burden, fewer side effects. Virus in blood can be reduced to undetectable levels for years. Why not maintain the status quo and go with life-long ART? Immune inflammation reduces lifespan!

Hunt et al JID 2003, PLoS ONE 2011 and unpublished HIV- (n = 132) HIV+ ART (n = 65) HIV+ Untreated (n = 82) Immune inflammation, as measured by T- cell activation, is lower in treated than untreated adults, but consistently higher than “normal”

Hunt et al JID 2003, PLoS ONE 2011 and unpublished HIV- (n = 132) HIV+ ART (n = 65) HIV+ Untreated (n = 82) Immune inflammation, as measured by T-cell activation, is lower in treated than untreated adults, but consistently higher than “normal” Individuals on ART develop “aging” diseases earlier in life. Immune inflammation leads to co- morbidities including cardiovascular issues and diabetes that can reduce an HIV- infected individuals lifespan by 5-6 years- even though the individual is on ARVs and virus is undetectable in blood! Individuals on ART develop “aging” diseases earlier in life. Immune inflammation leads to co- morbidities including cardiovascular issues and diabetes that can reduce an HIV- infected individuals lifespan by 5-6 years- even though the individual is on ARVs and virus is undetectable in blood!

The changing face of ART 15 years ago! Today! Tomorrow?

Is HIV curable? Lessons from early ART initiation!

Sterilizing cure- all virus has been eliminated from the body Functional cure- virus remains but doesn’t rebound after antiviral cocktails are removed

Early phases of HIV-1 infection

20 adults (and one child) who started therapy early (but not in “hyperacute” stage), remained on therapy for years, and had no rebound after stopping therapy Virus still remains detectable in blood but under control-even in absence of ART- functional cure?

“Mississippi baby” born to an HIV-positive mother who had not received antiretroviral treatment during pregnancy. Infant was treated from 30 hours after birth but parents stopped therapy after 18 months. Infant remained off drugs for next 27 months yet virus remained undetectable in blood until virus rebounded two months shy of infant’s 4 th birthday.

44 million HIV infections; 1 validated cure, Timothy Brown (Berlin Patient) What was different about this case?

44 million HIV infections; 1 validated cure, Timothy Brown (Berlin Patient) What was different about this case? Infected On ARVs until 2006 where he develops acute myeloid leukemia. Fails chemotherapy then receives two bone marrow transplants from a donor who had a mutation in CCR5- a co-receptor for the virus. 8 years later, virus is undetectable in all tissues even though Timothy Brown is not on therapy.

CCR5 alleles

ATI: Patient B 27

ATI: Patient B 28 Suggests presence of CCR5 null stem cells is necessary for the cure in the setting of BMT Suggests presence of CCR5 null stem cells is necessary for the cure in the setting of BMT

Genetic approaches to eliminating HIV infection!

Why can’t we use CCR5 null BMT to cure HIV infection? Identification of immunologically matched donors with CCR5 mutation is challenging BMT carries a 25% mortality rate. Costs are significant ~300K BMT to cure HIV is unethical when ARVs sustain survival. Physician can not increase risk for patient. Scientists are developing approaches to create the CCR5 mutation in an infected individuals stem cells

Gene therapy for cure of HIV-1

Challenges behind genetic therapies to cure HIV-1 infection! Cost- $100K! Most of the 40 million infections worldwide are in resource-limited regions where average per capita healthcare expenditure is several hundred dollars Long-term concerns with modifying an individuals DNA.

Eliminating the latent reservoir using kick and kill approaches!

Comparison of latent and active HIV infection

Time on HAART (years) Latent Cell Frequency Slow decay of latently infected CD4 + T cells Time to eradication > 73.4 years Courtesy Bob Siliciano

Shock and kill approach for cure of HIV!

“Kick and Kill” Pilot study of vorinostat (SAHA) in long-term treated adults

Changes in viral RNA levels were very modest Unclear whether viral protein- the essential target of “shock and kill” strategy, was produced Unclear whether latency is the same in all cells Changes in viral RNA levels were very modest Unclear whether viral protein- the essential target of “shock and kill” strategy, was produced Unclear whether latency is the same in all cells

If there are different faucets or reservoirs, water in each sink empties at different rates

Immune-based approaches to eliminate the viral reservoirs!

CMV engineered as a live HIV/SIV vaccine causes high levels of tissue-based “killer” CD8+ T cells that target novel parts of the virus Vector stimulates “unconventional” MHC II/HLA E restricted CD8+ T cell responses that are potent, effector memory differentiated, widely distributed and indefinitely persistent These cells clear latency during early infection, resulting in first clear documentation of a “cure” in this model

Getting CD8 T-cells to the right place!

Baseline reservoir size and timing of viral rebound Jonathan Li

Baseline reservoir size and timing of viral rebound Jonathan Li Implications of active reservoir: Infected cells may be recognizeable to immune system- “shock and kill” may not be required. Therefore, boosting antiviral immunity may help clear the viral reservoirs Implications of active reservoir: Infected cells may be recognizeable to immune system- “shock and kill” may not be required. Therefore, boosting antiviral immunity may help clear the viral reservoirs